ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 173

S100A8/A9, a Potent Serum and Molecular Imaging Biomarker for Synovial Inflammation and Joint Destruction in Seronegative Experimental Arthritis

Edwin J. W. Geven1, Martijn H. J. van den Bosch1, Shahla Abdolahi-Roodsaz1, Annet W. Sloetjes1, Sven Hermann2, Michael Schäfers2, Marije I. Koenders1, Dirk Föll3, Johannes Roth4, Thomas Vogl4 and Peter L. E. M. van Lent1, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2European Institute for Molecular Imaging, University of Münster, Münster, Germany, 3Department of Pediatric Rheumatology and Immunology, University of Münster, Münster, Germany, 4Institute of Immunology, University of Münster, Münster, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Arthritis, Biomarkers, Imaging, inflammation and joint destruction

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Innate Immunity and Rheumatic Disease - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Seronegative joint diseases, including psoriatic arthritis and juvenile idiopathic arthritis, are characterized by the lack of autoantibodies, which are relevant biomarkers for predicting disease activity in rheumatoid arthritis. Promising alternative biomarkers are the Damage Associated Molecular Patterns (DAMPs), S100A8, S100A9 and the heterodimer S100A8/A9. These proteins are specifically expressed and released by infiltrating phagocytes and may therefore serve as relevant biomarkers for joint inflammation and destruction in seronegative arthritis. In this study we determined the biomarker potential of serum S100A8/A9 and in vivo imaging of synovial S100A8 to asses joint inflammation and damage in the IL-1 receptor antagonist deficient (IL-1Ra-/-) mice, a mouse model for seronegative arthritis in which serum autoantibodies are not correlated to disease activity.

Methods: Serum levels of S100A8/A9 and various cytokines were monitored during arthritis development in IL-1Ra-/- mice using ELISA and Luminex and were correlated to macroscopic and microscopic parameters for joint inflammation and damage. Local S100A9 expression and matrix metalloproteinase (MMP) mediated cartilage damage in the ankle joints were investigated by immunohistochemistry. In addition local S100A8 and activated MMPs were monitored in vivo by optical imaging using anti-S100A8-Cy7 and AF-489-Cy7, a specific tracer for activated MMPs.

Results: Starting at week 8, serum levels of S100A8/A9 were significantly increased (1640 ± 1008 ng/ml at week 16) in IL-1Ra-/- mice compared to WT BALB/c control mice (429 ± 191 ng/ml, P = 0.005) and strongly correlated to joint swelling (r = 0.766, P < 0.0001), while serum levels of IL-1β, IL-6, TNF-α, IL-17, IL-4 or IFN-α did not. In addition, high serum S100A8/A9 levels at week 10 were predictive for increased joint swelling at week 16 (r = 0.576, P = 0.0002). Next to macroscopic swelling, increased serum S100A8/A9 also correlated to microscopic cell influx (r = 0.794, P < 0.0001) and was reflected by local expression of S100A9 within the synovium, indicating the activated synovial lining as the source of increased serum S100A8/A9. Local expression of S100-DAMPs could also be monitored non-invasively by in vivo optical imaging using anti-S100A8-Cy7. Next to a biomarker for inflammation, S100-DAMPs may also be used for assessing joint damage. Indeed, arthritic IL-1Ra-/- mice showed increased cartilage damage (r = 0.687, P < 0.0001) which coincided with MMP-mediated neoepitope (VDIPEN) expression and in vivo imaging of activated MMPs.

Conclusion:  These findings underline the potential of S100-DAMPs as a systemic and local biomarker in seronegative arthritis, not only for assessing inflammation but also joint damage.


Disclosure: E. J. W. Geven, None; M. H. J. van den Bosch, None; S. Abdolahi-Roodsaz, None; A. W. Sloetjes, None; S. Hermann, None; M. Schäfers, None; M. I. Koenders, None; D. Föll, None; J. Roth, None; T. Vogl, None; P. L. E. M. van Lent, None.

To cite this abstract in AMA style:

Geven EJW, van den Bosch MHJ, Abdolahi-Roodsaz S, Sloetjes AW, Hermann S, Schäfers M, Koenders MI, Föll D, Roth J, Vogl T, van Lent PLEM. S100A8/A9, a Potent Serum and Molecular Imaging Biomarker for Synovial Inflammation and Joint Destruction in Seronegative Experimental Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/s100a8a9-a-potent-serum-and-molecular-imaging-biomarker-for-synovial-inflammation-and-joint-destruction-in-seronegative-experimental-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/s100a8a9-a-potent-serum-and-molecular-imaging-biomarker-for-synovial-inflammation-and-joint-destruction-in-seronegative-experimental-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology